PDCD1 and melanoma: Mouse melanoma resistance models treated with UNC0642 (a G9a inhibitor) in combination with anti-PD-1 therapy significantly reduced H3K9 levels in the LC3B II promoter region activating cellular autophagic responses and increasing PD-L1 levels, enhancing the blockade response to PD-1 immune checkpoint inhibitors (35).